In a double-blind crossover study, 8 patients with angina and with angiographically documented coronary artery disease received two weeks apart 5 successive doses of 4 mg tolamolol (20 mg) and .5 successive doses of 2 mg propranolol (Io mg) administered intravenously within 25 minutes. After 20 mg tolamolol, a significant decrease occurred in heart rate (N4%), in aortic systolic pressure (4%), in left ventricular systolic pressure (4%), in left ventricular dp/pt (25%), in cardiac index (i8%), in stroke index (6%), in systolic ejection rate (rx%), and in left ventricular work (24%), and a significant increase in left ventricular end-diastolic pressure (39%) and in systemic vascular resistance (I7%). After Io mg propranolol, a significant decrease occurred in heart rate (I3%), in aortic systolic pressure (3%), in left ventricular systolic pressure (3%)°, in left ventricular dp/dt (28%), in cardiac index (22%), in stroke index (io%), in systolic ejection rate (i6%), and in left ventricular work (27%), and a significant increase in left ventricular end-diastolic pressure (47%) and in systemic vascular resistance (25%). No significant difference in haemodynamics was observed between these equipotent doses of intravenous tolamolol andpropranolol except that tolamolol caused a significantly smaller increase in systemic vascular resistance.
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Tolamolol (UK 6558) is a new cardioselective betaadrenergic blocking agent (Briant et al., I973) which was found (Hillis, I974) not to have the direct depressant action of propranolol on myocardial contractility. We found both intravenous (Aronow et al., 1972) and oral (Aronow et al., I973) tolamolol to be useful in the treatment of certain cardiac arrhythmias. Sood and Havard (I9973) found that tolamolol increased the exercise tolerance of patients with angina. These investigators also found that doses of intravenous tolamolol capable of blocking cardiac sympathetic beta-receptors did not significantly affect the forced expiratory volume in i second in these patients.
A cardioselective beta-adrenergic blocking drug which produces less myocardial depression than propranolol would have therapeutic advantages over propranolol. Tfferefore, this double-blind crossover study was performed to evaluate the effects of equipotent doses of intravenous tolamolol versus propranolol on cardiovascular haemodynamics in the same patients. (Snedecor and Cochran, I967) .
Results
No adverse effects occurred in any patient during this study. Effect of tolamolol versus propranolol on cardiovascular haemodynamics in patients with angina Io8I Discussion Our data on the effect of intravenous propranolol on heart rate, aortic pressure, left ventricular systolic and end-diastolic pressure, left ventricular dp/dt, cardiac index, stroke index, systolic ejection rate, left ventricular minute work, and systemic vascular resistance agree in general with those previously reported (Sowton and Hamer, I966; Nakano and Kusakari, I966; Wolfson et al., I966; Bloomfield and Sowton, I967; Robin et al., I967; Parker, West, and Di Giorgi, I968; Lewis and Brink, I968) . Our data also indicate that equipotent doses of intravenous tolamolol and propranolol produce similar changes in heart rate, aortic pressure, left ventricular systolic and end-diastolic pressure, left ventricular dp/dt, cardiac index, stroke index, systolic ejection rate, and left ventricular minute work.
Briant and associates (I973) showed that practolol and tolamolol produced greater antagonism of the chronotropic and inotropic responses to intravenous isoprenaline than of the vasodilator response to either intravenous or intra-arterial isoprenaline and, therefore, produced cardioselective betareceptor blockade. Our data indicate that after equipotent doses of intravenous tolamolol and propranolol are used, significantly less rise in systemic vascular resistance occurs after intravenous tolamolol than after intravenous propranolol. These findings are consistent with a selective action of tolamolol on the cardiac beta-adrenoceptors.
In conclusion, tolamolol is a new beta-adrenergic blocking drug which, like propranolol, may produce depression of myocardial activity. However, tolamolol may have a therapeutic advantage over propranolol by virtue of a cardioselective betaadrenergic blocking action. 
